NASDAQ:ENDP - Endo International Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.00
  • Forecasted Upside: 383.87 %
  • Number of Analysts: 4
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.62
▼ -0.54 (-46.55%)

This chart shows the closing price for ENDP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Endo International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENDP

Analyst Price Target is $3.00
▲ +383.87% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Endo International in the last 3 months. The average price target is $3.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 383.87% upside from the last price of $0.62.

This chart shows the closing price for ENDP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 investment analysts is to hold stock in Endo International. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 3 sell ratings
11/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 3 sell ratings
2/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 4 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 3 sell ratings
8/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 3 sell ratings
11/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 3 sell ratings
2/18/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
4/19/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
5/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2022BMO Capital MarketsLower Price Target$4.00 ➝ $2.00High
5/9/2022BarclaysLower Price Target$2.00 ➝ $1.00High
5/6/2022Piper SandlerDowngradeNeutral ➝ Underweight$3.00 ➝ $1.00Low
3/9/2022CitigroupLower Price TargetBuy$11.00 ➝ $6.00High
3/3/2022BMO Capital MarketsLower Price Target$8.00 ➝ $4.00High
3/2/2022Piper SandlerLower Price TargetNeutral$5.00 ➝ $3.00High
3/2/2022BarclaysDowngradeEqual Weight ➝ Underweight$5.00 ➝ $2.00High
12/16/2021BarclaysLower Price TargetEqual Weight$7.00 ➝ $5.00High
8/31/2021Piper SandlerDowngradeOverweight ➝ Neutral$10.00 ➝ $3.00Medium
8/9/2021Royal Bank of CanadaLower Price TargetSector Perform$6.00 ➝ $5.00Medium
5/17/2021CitigroupBoost Price TargetBuy$10.00 ➝ $11.00Low
4/7/2021Royal Bank of CanadaInitiated CoverageSector Perform$7.00High
3/8/2021BarclaysBoost Price TargetPositive ➝ Equal Weight$6.00 ➝ $7.00High
3/4/2021CitigroupLower Price Target$11.00 ➝ $10.00High
3/3/2021Morgan StanleyBoost Price TargetUnderweight$5.00 ➝ $7.00High
2/8/2021SVB LeerinkReiterated RatingMarket PerformLow
1/19/2021CitigroupBoost Price Target$7.00 ➝ $9.00High
1/4/2021Piper SandlerBoost Price TargetOverweight$6.00 ➝ $12.00N/A
11/12/2020Morgan StanleyBoost Price TargetUnderweight$3.00 ➝ $4.00Medium
10/9/2020Piper SandlerBoost Price TargetOverweight$5.00 ➝ $6.00High
7/27/2020The Goldman Sachs GroupInitiated CoverageSell$3.00High
7/8/2020SunTrust BanksReiterated RatingBuyHigh
6/11/2020Royal Bank of CanadaReiterated RatingHold$6.00Medium
5/10/2020Royal Bank of CanadaReiterated RatingHold$6.00Low
4/24/2020CitigroupInitiated CoverageBuy$7.00High
4/15/2020Piper SandlerLower Price TargetOverweight$7.00 ➝ $6.00Medium
4/2/2020Royal Bank of CanadaReiterated RatingHold$6.00Low
4/2/2020Morgan StanleyLower Price TargetUnderweight$4.00 ➝ $3.00Low
1/3/2020Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$5.00 ➝ $7.00Low
8/9/2019Morgan StanleySet Price TargetSell$2.00N/A
8/8/2019Royal Bank of CanadaReiterated RatingHold$6.00High
8/7/2019MizuhoReiterated RatingHold$6.00High
7/31/2019MizuhoReiterated RatingHold$6.00High
7/15/2019Morgan StanleyDowngradeEqual Weight ➝ Underweight$8.00 ➝ $3.00Medium
7/11/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$11.00 ➝ $6.00High
6/17/2019CitigroupDowngradeBuy ➝ Neutral$19.00 ➝ $5.00Medium
6/12/2019Cantor FitzgeraldLower Price TargetNeutral$18.00 ➝ $4.75High
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$6.00High
5/14/2019MizuhoSet Price TargetHold$9.00Low
5/13/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$9.00High
3/27/2019GabelliReiterated RatingHoldMedium
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$13.00Medium
3/18/2019JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $10.00Low
3/5/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
3/1/2019Piper Jaffray CompaniesReiterated RatingHoldHigh
11/26/2018MizuhoLower Price TargetNeutral$15.00High
11/9/2018CowenReiterated RatingHold$9.00Low
10/19/2018Cantor FitzgeraldBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $18.00Low
9/11/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$14.00 ➝ $15.00Low
8/17/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $17.00Low
8/14/2018MizuhoBoost Price TargetNeutral$17.00Low
8/13/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$26.00High
8/10/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$9.00 ➝ $16.00Low
8/9/2018SVB LeerinkBoost Price TargetOutperform ➝ Market Perform$12.00 ➝ $18.00High
8/9/2018Stifel NicolausBoost Price TargetHold ➝ Hold$10.00 ➝ $17.00Low
8/9/2018CitigroupBoost Price TargetBuy ➝ Buy$11.00 ➝ $19.00Low
8/8/2018Cantor FitzgeraldSet Price TargetHold$12.00High
8/7/2018B. RileyBoost Price TargetBuy ➝ Buy$13.00 ➝ $15.00Low
7/23/2018Cantor FitzgeraldSet Price TargetHold$12.00Medium
7/18/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$11.00Low
7/11/2018CitigroupReiterated RatingBuyLow
6/28/2018B. RileyBoost Price TargetBuy ➝ Buy$10.00 ➝ $13.00High
6/27/2018CitigroupUpgradeNeutral ➝ Buy$11.00High
6/1/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$10.00Medium
5/13/2018OppenheimerReiterated RatingHoldLow
5/8/2018Cantor FitzgeraldSet Price TargetHold$7.00High
4/4/2018MizuhoDowngradeBuy ➝ Neutral$12.00 ➝ $7.00High
3/10/2018BarclaysSet Price TargetHold$9.00Low
3/5/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$10.00 ➝ $9.00High
2/28/2018GabelliDowngradeBuy ➝ HoldHigh
2/27/2018OppenheimerReiterated RatingHoldHigh
2/27/2018Cantor FitzgeraldSet Price TargetHold$7.00Low
2/26/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
2/23/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.00High
2/14/2018B. RileyInitiated CoverageBuy ➝ Buy$10.00High
1/11/2018Cantor FitzgeraldSet Price TargetHold$7.00Low
1/3/2018MizuhoReiterated RatingBuy ➝ Buy$14.00 ➝ $12.00High
1/2/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$12.00High
12/12/2017GuggenheimInitiated CoverageNeutral ➝ Neutral$8.50Low
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$7.00N/A
11/10/2017MizuhoReiterated RatingBuyN/A
11/10/2017BMO Capital MarketsLower Price TargetMarket Perform$11.00 ➝ $10.00N/A
11/10/2017Cantor FitzgeraldLower Price TargetNeutral$9.00 ➝ $7.00N/A
11/10/2017CitigroupLower Price TargetNeutral$9.00 ➝ $7.00N/A
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$9.00 ➝ $8.00N/A
10/30/2017Cantor FitzgeraldSet Price TargetHold$9.00N/A
10/17/2017Royal Bank of CanadaSet Price TargetHold$9.00N/A
9/28/2017The Goldman Sachs GroupInitiated CoverageSell ➝ Sell$7.00High
9/17/2017Piper Jaffray CompaniesReiterated RatingHold$9.00Medium
9/12/2017MizuhoReiterated RatingBuy$19.00 ➝ $14.00Low
8/11/2017BMO Capital MarketsReiterated RatingMarket Perform$15.00 ➝ $11.00Low
8/10/2017Morgan StanleyLower Price TargetEqual Weight$12.00 ➝ $8.00Low
8/10/2017CowenReiterated RatingHold$16.00High
8/10/2017CitigroupReiterated RatingNeutral$14.00 ➝ $11.00High
8/10/2017MizuhoReiterated RatingBuy$19.00High
8/10/2017Royal Bank of CanadaSet Price TargetHold$15.00 ➝ $9.00High
8/9/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$15.00 ➝ $13.00Low
8/9/2017Royal Bank of CanadaReiterated RatingSector Perform$15.00 ➝ $9.00High
8/8/2017OppenheimerReiterated RatingHoldHigh
8/8/2017Cantor FitzgeraldSet Price TargetHold$12.00 ➝ $9.00Medium
7/23/2017OppenheimerReiterated RatingHoldHigh
7/16/2017Royal Bank of CanadaSet Price TargetHold$15.00Medium
7/7/2017Deutsche Bank AktiengesellschaftLower Price TargetBuy$18.00 ➝ $15.00Medium
6/17/2017GuggenheimInitiated CoverageHold$12.00Medium
6/16/2017Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$12.00Low
6/14/2017William BlairReiterated RatingMarket PerformLow
6/12/2017Royal Bank of CanadaSet Price TargetHold$15.00Low
6/9/2017Stifel NicolausDowngradeBuy ➝ Hold$22.00 ➝ $15.00High
6/8/2017OppenheimerReiterated RatingHoldHigh
5/25/2017MizuhoReiterated RatingBuy ➝ Buy$18.00 ➝ $19.00Low
(Data available from 5/19/2017 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/21/2021
  • 12 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/20/2021
  • 5 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/20/2021
  • 10 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/19/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/18/2022
  • 5 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
3/20/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/19/2022
  • 4 very positive mentions
  • 16 positive mentions
  • 14 negative mentions
  • 1 very negative mentions
5/19/2022

Current Sentiment

  • 4 very positive mentions
  • 16 positive mentions
  • 14 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Endo International logo
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $0.62
Low: $0.36
High: $1.14

50 Day Range

MA: $2.17
Low: $1.10
High: $2.74

52 Week Range

Now: $0.62
Low: $0.36
High: $7.07

Volume

55,135,161 shs

Average Volume

5,403,053 shs

Market Capitalization

$145.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Endo International?

The following Wall Street research analysts have issued reports on Endo International in the last twelve months: Barclays PLC, BMO Capital Markets, Citigroup Inc., Piper Sandler, Royal Bank of Canada, StockNews.com, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ENDP.

What is the current price target for Endo International?

0 Wall Street analysts have set twelve-month price targets for Endo International in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 383.9%.
View the latest price targets for ENDP.

What is the current consensus analyst rating for Endo International?

Endo International currently has 2 sell ratings, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ENDP, but not buy more shares or sell existing shares.
View the latest ratings for ENDP.

How do I contact Endo International's investor relations team?

Endo International's physical mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company's listed phone number is (531) 268-2000 and its investor relations email address is [email protected] The official website for Endo International is www.endo.com. Learn More about contacing Endo International investor relations.